<DOC>
	<DOC>NCT02752776</DOC>
	<brief_summary>Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis patients with or without prior exposure to systemic therapy.</brief_summary>
	<brief_title>A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Men or women aged at least 18 years at time of Screening. Moderate to severe plaquetype psoriasis diagnosed for at least 3 months prior to Screening and candidate for systemic therapy. Other protocol defined inclusion criteria may apply. Please refer to the protocol. Forms of psoriasis other than moderate to severe plaquetype psoriasis, e.g. druginduced psoriasis at Screening. Patients with previous treatment with any agent targeting interleukin (IL)17 directly or IL17 receptor A (e.g. secukinumab, ixekizumab, or brodalumab). Pregnant or nursing (lactating) women Women of childbearing potential unless they use effective contraception Other protocoldefined exclusion criteria may apply. Please refer to the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Moderate to severe plaque psoriasis</keyword>
</DOC>